Vertex Pharmaceuticals (VRTX) Revenue (2009 - 2026)

Vertex Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• On a quarterly basis, Revenue rose 7.82% year-over-year to $3.0 billion in Q1 2026; TTM through Mar 2026 was $12.2 billion, a 10.08% increase from a year earlier, with the FY2025 full-year figure at $12.0 billion, up 8.9% from the prior year.
• Revenue eased to $3.0 billion in Q1 2026 per VRTX's latest filing, from $3.2 billion in the prior quarter.
• Across five years, Revenue topped out at $3.2 billion in Q4 2025 and bottomed at $2.1 billion in Q1 2022.
• The 5-year median for Revenue is $2.6 billion (2024), against an average of $2.6 billion.
• Across the five-year window, Revenue rose 22.46% in 2022 and increased 2.96% in 2025, its largest moves.
• Year by year, Revenue stood at $2.3 billion in 2022, then advanced by 9.34% to $2.5 billion in 2023, then climbed by 15.66% to $2.9 billion in 2024, then climbed by 9.55% to $3.2 billion in 2025, then retreated by 6.37% to $3.0 billion in 2026.
• Per Business Quant, the three latest VRTX Revenue figures stand at $3.0 billion (Q1 2026), $3.2 billion (Q4 2025), and $3.1 billion (Q3 2025).